Constitutional telomerase mutations are genetic risk factors for cirrhosis

Hepatology

Volumn 53, Issue 5, 2011, Pages 1600-1607

  Calado, Rodrigo T ^a   Brudno, Jennifer ^a,b   Mehta, Paulomi ^a,b   Kovacs, Joseph J ^c   Wu, Colin ^a   Zago, Marco A ^d   Chanock, Stephen J ^c   Boyer, Thomas D ^e   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDYLTRANSFERASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE RNA TEMPLATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL LINE; CELL LYSATE; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE VECTOR; GENETIC RISK; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; LEUKOCYTE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; SCHOOL CHILD; SCREENING TEST; TELOMERE; UNITED STATES;

ADULT; AGED; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUTATION, MISSENSE; RISK FACTORS; TELOMERASE; YOUNG ADULT;

EID: 79955119666     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24173     Document Type: Article

References (52)

1. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-673.
2. Olovnikov AM. [Principle of marginotomy in template synthesis of polynucleotides.] Dokl Akad Nauk SSSR 1971; 201: 1496-1499.
3. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353-2365.
4. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol 2007; 3: 640-646.
5. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-413.
6. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276: 561-567.
7. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007; 315: 1850-1853.
8. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998; 19: 32-38.
9. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason P, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413: 432-435.
10. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand EM, Zeng W, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003; 362: 1628-1630.
11. Yamaguchi H, Calado RT, Ly H, Baerlocher GM, Kajigaya S, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Eng J Med 2005; 352: 1413-1424.
12. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll SG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Eng J Med 2007; 356: 1317-1326.
13. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Nat Acad Sci U S A 2007; 104: 7552-7557.
14. Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Nat Acad Sci U S A 2009; 106: 1187-1192.
15. Kirwan M, Vulliamy T, Marrone A, Walne AJ, Beswick R, Hillmen P, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009; 30: 1567-1573.
16. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41: 221-227.
17. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40: 1404-1406.
18. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41: 899-904.
19. Hosgood HD3, Cawthon RM, He X, Chanock SJ, Lan Q. Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. Lung Cancer 2009; 66: 157-161.
20. Petersen GM, Amundadottir L, Fuchs CS, Fraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228.
21. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110: 768-779.
22. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215-231.
23. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008; 111: 4446-4455.
24. Rocha V, Devergie A, Socie G, Ribaud P, Esperou H, Parquet N, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haem 1998; 103: 243-248.
25. Calado RT, Regal JA, Kleiner DE, Schrump DS, Peterson NR, Pons V, et al. A spectrum of severe familal liver disorders associate with telomerase mutations. PLoS One 2009; 4: e7926.
26. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258.
27. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-942.
28. Kitada T, Seki S, Kawakita N, Kuroki T, Monna T. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995; 211: 33-39.
29. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30.
30. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-114.
31. Ly H, Schertzer M, Jastaniah W, Davis J, Yong SL, Ouyang Q, et al. Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita. Blood 2005; 106: 1246-1252.
32. Vulliamy T, Marrone A, Dokal I, Mason PJ. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002; 359: 2168-2170.
33. Wilson DB, Ivanovich J, Whelan A, Goodfellow PJ, Bessler M. Human telomerase RNA mutations and bone marrow failure. Lancet 2003; 361: 1993-1994.
34. Liang J, Yagasaki H, Kamachi Y, Hama A, Matsumoto K, Kato K, et al. Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. Haematologica 2006; 91: 656-658.
35. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352: 1413-1424.
36. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851.
37. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002, June 10-12, 2002. HEPATOLOGY 2002; 36(5 Suppl 1): S3-S20.
38. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-1687.
39. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 1085-1093.
40. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. HEPATOLOGY 2003; 38: 1468-1476.
41. Satsangi J, Chapman RW, Haldar N, Donaldson P, Mitchell S, Simmons J, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001; 121: 124-130.
42. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. HEPATOLOGY 2003; 37: 493-503.
43. Ku NO, Lim JK, Krams SM, Esquivel CO, Keeffe EB, Wright TL, et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology 2005; 129: 885-893.
44. Hao L-Y, Armanios M, Strong MD, Karim B, Feldser DM, Huso D, et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005; 123: 1121-1131.
45. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-985.
46. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43: 2573-2576.
47. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524.
48. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. HEPATOLOGY 2000; 32: 1131-1137.
49. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418-423.
50. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
51. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004; 36: 447-449.
52. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Nat Acad Sci U S A 2008; 105: 13051-13056.